Tarsus Pharmaceuticals (TARS) Competitors $40.20 -1.20 (-2.90%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$40.80 +0.60 (+1.49%) As of 06/25/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARS vs. ELAN, LEGN, GRFS, TLX, TGTX, LNTH, NUVL, AXSM, AKRO, and PCVXShould you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Elanco Animal Health (ELAN), Legend Biotech (LEGN), Grifols (GRFS), Telix Pharmaceuticals (TLX), TG Therapeutics (TGTX), Lantheus (LNTH), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Tarsus Pharmaceuticals vs. Its Competitors Elanco Animal Health Legend Biotech Grifols Telix Pharmaceuticals TG Therapeutics Lantheus Nuvalent Axsome Therapeutics Akero Therapeutics Vaxcyte Elanco Animal Health (NYSE:ELAN) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings. Do analysts prefer ELAN or TARS? Elanco Animal Health presently has a consensus target price of $15.17, suggesting a potential upside of 10.14%. Tarsus Pharmaceuticals has a consensus target price of $66.67, suggesting a potential upside of 65.84%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elanco Animal Health 0 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.43Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has stronger earnings and valuation, ELAN or TARS? Elanco Animal Health has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElanco Animal Health$4.44B1.54$338M$0.7418.61Tarsus Pharmaceuticals$182.95M9.23-$115.55M-$2.73-14.73 Does the media favor ELAN or TARS? In the previous week, Elanco Animal Health and Elanco Animal Health both had 4 articles in the media. Tarsus Pharmaceuticals' average media sentiment score of 0.59 beat Elanco Animal Health's score of 0.41 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tarsus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of ELAN or TARS? 97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 0.9% of Elanco Animal Health shares are owned by company insiders. Comparatively, 9.0% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, ELAN or TARS? Elanco Animal Health has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Is ELAN or TARS more profitable? Elanco Animal Health has a net margin of 8.43% compared to Tarsus Pharmaceuticals' net margin of -44.91%. Elanco Animal Health's return on equity of 7.54% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Elanco Animal Health8.43% 7.54% 3.57% Tarsus Pharmaceuticals -44.91%-39.72%-25.74% SummaryElanco Animal Health beats Tarsus Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARS vs. The Competition Export to ExcelMetricTarsus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.74B$2.85B$5.42B$8.73BDividend YieldN/A2.69%5.37%4.21%P/E Ratio-14.7320.9825.0319.35Price / Sales9.23301.46404.73112.10Price / CashN/A43.0735.9456.46Price / Book6.857.337.985.50Net Income-$115.55M-$55.19M$3.14B$248.18M7 Day Performance-2.12%1.09%0.86%0.75%1 Month Performance-6.47%8.30%5.13%4.44%1 Year Performance59.14%0.64%38.78%16.85% Tarsus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARSTarsus Pharmaceuticals1.9299 of 5 stars$40.20-2.9%$66.67+65.8%+55.8%$1.74B$182.95M-14.7350ELANElanco Animal Health2.4382 of 5 stars$13.36-0.7%$15.17+13.5%-22.9%$6.68B$4.44B18.059,000LEGNLegend Biotech2.4015 of 5 stars$33.85-0.4%$76.20+125.1%-23.2%$6.25B$627.24M-57.372,609GRFSGrifols3.7759 of 5 stars$8.37-4.6%$10.30+23.1%+21.6%$6.03B$7.81B7.1523,822TLXTelix PharmaceuticalsN/A$16.39-4.4%$22.00+34.2%N/A$5.80B$516.72M0.00N/AGap UpHigh Trading VolumeTGTXTG Therapeutics3.1963 of 5 stars$36.56+1.5%$40.80+11.6%+94.2%$5.72B$329M152.33290Positive NewsLNTHLantheus4.2313 of 5 stars$80.81+2.0%$130.50+61.5%-1.7%$5.48B$1.53B22.96700Analyst ForecastNUVLNuvalent2.4198 of 5 stars$75.98+1.3%$115.50+52.0%-1.6%$5.39BN/A0.0040Trending NewsAnalyst ForecastAXSMAxsome Therapeutics4.6661 of 5 stars$101.65+1.0%$172.33+69.5%+31.2%$4.96B$385.69M-17.62380Insider TradeAKROAkero Therapeutics3.6311 of 5 stars$54.03-0.3%$82.50+52.7%+134.2%$4.32BN/A-27.7130PCVXVaxcyte3.0309 of 5 stars$33.25+1.2%$136.50+310.5%-55.6%$4.24BN/A-8.33160Positive News Related Companies and Tools Related Companies Elanco Animal Health Alternatives Legend Biotech Alternatives Grifols Alternatives Telix Pharmaceuticals Alternatives TG Therapeutics Alternatives Lantheus Alternatives Nuvalent Alternatives Axsome Therapeutics Alternatives Akero Therapeutics Alternatives Vaxcyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARS) was last updated on 6/26/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredIs Tesla a buy right now?Wall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TARS Stock Free TARS Stock Alerts